Press "Enter" to skip to content

Tag: remdesivir

Remdesivir tied to 25% lower risk of in-hospital death in adults with COVID and no added oxygen

The antiviral drug remdesivir cut death rates 17% to 25% in adults hospitalized for COVID-19 who didn’t require supplemental oxygen at admission, suggests a large US study published yesterday in Open Forum Infectious Diseases.

The study, led by researchers from remdesivir (Veklury) developer Gilead Sciences, used a multicenter US hospital billing database to compare rates of in-hospital death among 58,188 patients on room air who received at least one dose of remdesivir within the first 2 days of hospital admission and 17,574 matched patients not given the drug. The drug is most effective when given early in infection, when viral replication is most active.

Comments closed

Ivermectin warnings, a new COVID-19 antiviral, a changing threshold for care: These are the WHO’s updated treatment guidelines

The World Health Organization (WHO) has updated its guidelines for the treatment of COVID-19 patients, including categories of hospitalization risk to help doctors tailor treatment, and recommendations surrounding a new antiviral designed specifically to tackle the disease.

Comments closed